According to Diabeteshealth.com, Glitazones, such as Actos, have seen a dramatic drop in usage over the past few years. Actos use among diabetes patients dropped from 41 percent in 2005 to 16 percent in 2012 due to drug’s link to cardiovascular issues and bladder cancer.
Metformin, another type 2 diabetes treatment, saw an increase in usage among patients and increased from 23 percent in 1997 to 53 percent in 2012. Long-acting insulins also saw an increase from almost no usage in 1997 to 18 percent in 2012.
Actos has also been directly linked to an increased risk of bladder cancer. Several studies have found that patients who use Actos for more than one year are 40% more likely to develop bladder cancer. The studies led to several countries restricting sales of the type II diabetes drug.